Precision Medicine Platform AIQ Solutions Takes CancerX Discovery Award

AIQ Solutions was awarded the inaugural Discovery Acceleration Award at the CancerX 2025 Accelerator graduation ceremony, recognizing their revolutionary potential to accelerate clinical trials and advance patient access to critical treatments.

AIQ Solutions is tackling one of oncology's most challenging realities: metastatic cancer lesions do not all respond to treatment equally. While much of cancer technology development has focused on early-stage treatment, AIQ addresses the complex reality faced by patients with advanced disease, where traditional one-size-fits-all approaches often fall short.

Their breakthrough solution, TRAQinform IQ, is a software medical device that provides novel information about quantification of change in regions of interest over time. This technology enables oncologists and clinicians to more precisely adjust therapies and optimize clinical outcomes by providing unprecedented insight into how individual lesions respond to treatment.

AIQ's platform enables providers to more accurately predict therapy response and precisely adjust treatment protocols to address the varied growth patterns of different lesions. By providing more precise measurements of treatment response, their technology could accelerate the development of new therapies and improve the efficiency of clinical trials.

"AIQ Solutions exemplifies how precision medicine can transform outcomes for our most challenging cases," said Kamal Jethwani, CancerX lead. "Their technology doesn't just improve individual patient care—it has the potential to revolutionize how we conduct clinical research and accelerate the path to new treatments for patients worldwide."

The Discovery Acceleration Award was designed to honor the startup showing the greatest potential to transform clinical trials and expand patient access. AIQ Solutions stood out among an impressive field of finalists, including First Ascent, Encapsulate, Dyania Health, and Arcascope, who were evaluated by CancerX champions and key accelerator stakeholders based on clinical trial impact potential, scientific rigor, and market validation.

Learn more about AIQ Solutions and TRAQinform IQ.

Read more about the CancerX Accelerator and how we're transforming cancer care through innovation here.